This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety, Tolerability, Pharmacokinetics and -Dynamics of Multiple Rising Oral Doses of BI 113823 in Patients Patients With Osteoarthritis of the Knee

This study has been terminated.
Sponsor:
Information provided by:
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01207973
First received: September 22, 2010
Last updated: November 4, 2013
Last verified: November 2013
  Purpose
The objective of the study is to investigate the safety and tolerability of BI 113823 in male and female patients with osteoarthritis, following oral administration of BI 113823 with repeated rising doses.

Condition Intervention Phase
Osteoarthritis Drug: BI 113823 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of Multiple Rising Oral Doses (50, 100, 200 and 350 mg qd and 100 mg Bid for 12 Days) of BI 113823 as Tablet in Male and Female Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Safety (Physical examination) [ Time Frame: 15 days ]
  • Safety (Vital signs) [ Time Frame: 15 days ]
  • Safety (12-lead ECG) [ Time Frame: 15 days ]
  • Safety (Clinical laboratory tests) [ Time Frame: 15 days ]
  • Safety (Adverse Events) [ Time Frame: 15 days ]
  • Tolerability (Assessment of tolerability by investigator) [ Time Frame: 15 days ]

Secondary Outcome Measures:
  • Measures of pharmacodynamic effects [ Time Frame: 15 days ]
  • Standard pharmacokinetic parameters for single dose and steady state conditions will be assessed [ Time Frame: 15 days ]

Enrollment: 36
Study Start Date: September 2010
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BI 113823
5 dose-groups of multiple oral doses of BI 113823
Drug: BI 113823
5 dose-groups of multiple oral doses of BI 113823

  Eligibility

Ages Eligible for Study:   35 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria patients with osteoarthritis

Exclusion criteria

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01207973

Locations
Germany
1272.2.1 Boehringer Ingelheim Investigational Site
Muenchen, Germany
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01207973     History of Changes
Other Study ID Numbers: 1272.2
2010-018541-62 ( EudraCT Number: EudraCT )
Study First Received: September 22, 2010
Last Updated: November 4, 2013

Additional relevant MeSH terms:
Osteoarthritis
Osteoarthritis, Knee
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases

ClinicalTrials.gov processed this record on June 28, 2017